Related Experiment Video

Updated: Oct 27, 2026

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice
03:40

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Haemopoietic cell transplantation in children with juvenile myelomonocytic leukaemia

M L MacMillan1, S M Davies, P J Orchard

  • 1Department of Pediatrics, University of Minnesota, Minneapolis 55455, USA.

British Journal of Haematology
|November 25, 1998
PubMed

Insights

Allogeneic hematopoietic cell transplantation (HCT) for juvenile myelomonocytic leukemia (JMML) showed high relapse rates. Further multicenter trials are needed to determine optimal HCT strategies for JMML patients.

Area of Science:

  • Pediatric Hematology
  • Oncology
  • Stem Cell Transplantation

Background:

  • Juvenile myelomonocytic leukemia (JMML) is a rare pediatric malignancy.
  • Allogeneic hematopoietic cell transplantation (HCT) is a potential curative option for JMML.
  • Optimal conditioning regimens and post-transplant management for JMML remain undefined.

Purpose of the Study:

  • To evaluate the outcomes of allogeneic HCT in children with active JMML.
  • To assess engraftment, relapse rates, and survival after HCT for JMML.
  • To discuss the role and future directions of HCT in JMML management.

Main Methods:

  • Seven children with JMML (age 11 months to 5.9 years) received allogeneic HCT.
  • Conditioning regimens included cyclophosphamide and total body irradiation (TBI), with busulfan in two cases.
  • Bone marrow or umbilical cord blood from related or unrelated donors was used.

Main Results:

  • Engraftment was achieved in all seven patients.
  • Six out of seven patients relapsed post-HCT.
  • Two patients achieved long-term remission (23+ and 30+ months post-transplant).

Conclusions:

  • Allogeneic HCT in children with active JMML is associated with a high risk of relapse.
  • Further cooperative multicenter trials are essential to establish optimal HCT protocols for JMML.
  • Long-term survival is possible, but relapse remains a significant challenge.

More Related Videos

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Hematopoiesis01:21

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...